Stay updated on Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Page revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:37:36.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    Administrative metadata such as last update dates and submission history was refreshed; no core study details, eligibility criteria, or outcomes appear to have changed.
    Difference
    0.2%
    Check dated 2026-04-02T15:40:35.000Z thumbnail image
  4. Check
    34 days ago
    Change Detected
    Summary
    A new page revision label v3.5.0 was added, replacing the previous v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-19T06:09:30.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-11T23:57:01.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Branding and attribution elements were added to the page footer, including references to Moffitt Cancer Center and helpful links. No study details or navigation were modified.
    Difference
    0.1%
    Check dated 2026-03-04T23:44:36.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Footer references to Moffitt Cancer Center and the 'Helpful Links' section were removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-18T16:16:14.000Z thumbnail image

Stay in the know with updates to Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.